135 related articles for article (PubMed ID: 9121269)
1. Hydroxyflutamide may not always be a pure antiandrogen.
Yeh S; Miyamoto H; Chang C
Lancet; 1997 Mar; 349(9055):852-3. PubMed ID: 9121269
[No Abstract] [Full Text] [Related]
2. Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells.
Yeh S; Kang HY; Miyamoto H; Nishimura K; Chang HC; Ting HJ; Rahman M; Lin HK; Fujimoto N; Hu YC; Mizokami A; Huang KE; Chang C
Endocrine; 1999 Oct; 11(2):195-202. PubMed ID: 10709768
[TBL] [Abstract][Full Text] [Related]
3. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.
Yeh S; Lin HK; Kang HY; Thin TH; Lin MF; Chang C
Proc Natl Acad Sci U S A; 1999 May; 96(10):5458-63. PubMed ID: 10318905
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic options in patients with hormone-refractory prostate cancer.
Anand N
Am J Med; 1996 Feb; 100(2):243-4. PubMed ID: 8629663
[No Abstract] [Full Text] [Related]
5. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
Kai L; Levenson AS
Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742
[TBL] [Abstract][Full Text] [Related]
6. Suppression of mutant androgen receptors by flutamide.
Ishioka J; Hara S; Isaacs JT; Tomura A; Nishikawa K; Kageyama Y
Int J Urol; 2009 May; 16(5):516-21. PubMed ID: 19389135
[TBL] [Abstract][Full Text] [Related]
7. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C
Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626
[TBL] [Abstract][Full Text] [Related]
8. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
Middleman MN; Lush RM; Figg WD
Pharmacotherapy; 1996; 16(3):376-81. PubMed ID: 8726595
[TBL] [Abstract][Full Text] [Related]
9. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer.
Hu YC; Yeh S; Yeh SD; Sampson ER; Huang J; Li P; Hsu CL; Ting HJ; Lin HK; Wang L; Kim E; Ni J; Chang C
J Biol Chem; 2004 Aug; 279(32):33438-46. PubMed ID: 15166229
[TBL] [Abstract][Full Text] [Related]
10. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
11. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells.
Yeh S; Chang C
Proc Natl Acad Sci U S A; 1996 May; 93(11):5517-21. PubMed ID: 8643607
[TBL] [Abstract][Full Text] [Related]
12. Effects of steroidal and non-steroidal antiandrogens on the androgen binding properties of the rat ventral prostate androgen receptor.
Steinsapir J; Mora G; Muldoon TG
Biochim Biophys Acta; 1991 Aug; 1094(1):103-12. PubMed ID: 1883848
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
Wang LG; Liu XM; Kreis W; Budman DR
Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
[TBL] [Abstract][Full Text] [Related]
15. Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization.
Kemppainen JA; Wilson EM
Urology; 1996 Jul; 48(1):157-63. PubMed ID: 8693644
[No Abstract] [Full Text] [Related]
16. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
Berrevoets CA; Veldscholte J; Mulder E
J Steroid Biochem Mol Biol; 1993 Dec; 46(6):731-6. PubMed ID: 8274406
[TBL] [Abstract][Full Text] [Related]
17. [Antiandrogen in prostate cancer].
Maeda O; Usami M
Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
[No Abstract] [Full Text] [Related]
18. Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy.
Van der Kwast TH; Têtu B; Fradet Y; Dupont A; Gomez J; Cusan L; Diamond P; Labrie F
Prostate; 1996 Apr; 28(4):227-31. PubMed ID: 8602398
[TBL] [Abstract][Full Text] [Related]
19. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
20. Antiandrogens prevent stable DNA-binding of the androgen receptor.
Farla P; Hersmus R; Trapman J; Houtsmuller AB
J Cell Sci; 2005 Sep; 118(Pt 18):4187-98. PubMed ID: 16141232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
